AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05927649
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin capsules
Trial: NCT04980144
Drug: 3% Diquafosol tetrasodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
Trial: NCT04753879
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane
Trial: NCT04753879
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar
Trial: NCT04753879
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A
Trial: NCT04753879
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A
Trial: NCT04753879
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda
Trial: NCT04753879
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza
Trial: NCT06367998
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin oral intake from the day before surgery to six weeks postoperatively
Trial: NCT05432089
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
Trial: NCT05041153
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06236152
Drug: Deltacortril
DrugBank: Prednisolone (DB00860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deltacortil 10mg was given orally once daily for 4 to 6 weeks
Trial: NCT06098742
Drug: Antareit
RxNorm normalized name: Antarelix
DrugBank: Teverelix (DB05624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
Trial: NCT03994965
Drug: Pimavanserin 34 milligrams (MG) [Nuplazid]
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
Trial: NCT06163898
Drug: Alnuctamab
RxNorm normalized name: Alnuctamab
DrugBank: Alnuctamab (DB17194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06163898
Drug: Mezigdomide
RxNorm normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05086614
Drug: Thymosin Alpha1
RxNorm normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
Trial: NCT06163898
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05688475
Drug: CC-122
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05688475
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06340087
Drug: Sucrose+ Hesperetin
RxNorm normalized name: hesperetin
DrugBank: Hesperetin (DB01094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
Trial: NCT00002037
Drug: Trifluridine
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05058677
Drug: aerosolized 2% lidocaine (20mg/ml)
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
Trial: NCT05058677
Drug: instilled 0.9% sodium chloride (NS)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
Trial: NCT05058677
Drug: instilled 2% lidocaine solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
Trial: NCT05097261
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
Trial: NCT05167643
Drug: Enituzumab injection+Abesili tablets+Anastrozole tablets
RxNorm normalized name: anastrozole Oral Tablet
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
Trial: NCT00004114
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004114
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05765513
Drug: HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
RxNorm normalized name: High molecular weight insulin human
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
Trial: NCT06138496
Drug: Cadonilimab Combined With Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3.7.1 Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles.
Trial: NCT05169580
Drug: Pociredir oral capsule(s)
RxNorm normalized name: S-2
DrugBank: Pociredir (DB18070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Pociredir
Trial: NCT05244902
Drug: 5% Dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients will receive oral 3mL/kg 5%Dextrose
Trial: NCT05252091
Drug: herombopag olamine tablets
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
Trial: NCT04372940
Drug: Tranexamic Acid Irrigation
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
Trial: NCT05874193
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin 2.5mg/kg in 42-day cycles. Every 6 weeks until PD, unacceptable toxicity or withdrawal of consent, whichever comes first
Trial: NCT05543746
Drug: Brexanolone
RxNorm normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
Trial: NCT04670471
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
Trial: NCT06580509
Drug: Tranexamic Acid Injectable Product
RxNorm normalized name: tranexamic acid Injectable Product
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg/ml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
Trial: NCT05927155
Drug: LABA
RxNorm normalized name: Malabar Nut Leaf
DrugBank: Labafenogene marselecobac (DB17618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 4 puffs of 2,5 µg of a long-acting beta2-agonist (LABA-olodaterol) administered via a spacer device
Trial: NCT05927155
Drug: LAMA
RxNorm normalized name: Alamag
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device
Trial: NCT06722911
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab 400 mg on Day 1 and 15 of a 28-day cycle (6 cycles) ; Patients will receive Nimotuzumab 600 mg on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
Trial: NCT06523101
Drug: PJ009
RxNorm normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Six participants in each dose level will be randomized to receive a single dose and/or multiple doses of PJ009 in a double-blind fashion.
Trial: NCT06123884
Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
Trial: NCT00468962
Drug: FACOS (functional food)
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06123884
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the usage and dosage should be determined by the investigator
Trial: NCT06123884
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
Trial: NCT06136585
Drug: 2 mg/kg sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
Trial: NCT06136585
Drug: 0.07 mg/kg neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
Trial: NCT06123884
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the usage and dosage should be determined by the investigator
Trial: NCT06123884
Drug: Paclitaxel for Injection
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the usage and dosage should be determined by the investigator
Trial: NCT00013910
Drug: NNC 90-1170
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06346743
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling
Trial: NCT05131152
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
Trial: NCT05086627
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
Trial: NCT05432466
Drug: ACER-002 (celiprolol) 200 mg BID
RxNorm normalized name: Acer Saccharum Pollen
DrugBank: Acer saccharum pollen (DB10369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACER-002 (celiprolol) 200 mg BID
Trial: NCT05440422
Drug: anifrolumab
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
Trial: NCT03025360
Drug: Larotrectinib (Vitrakvi, BAY2757556)
RxNorm normalized name: larotrectinib 100 MG [Vitrakvi]
DrugBank: Larotrectinib (DB14723)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
Trial: NCT06285409
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
Trial: NCT06285409
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
Trial: NCT06285409
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
Trial: NCT06285409
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing concentrations of oxytocin from 10-10 M to 10-5 M
Trial: NCT06285409
Drug: Ergonovine
RxNorm normalized name: Ergonovine
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing concentrations of ergometrine from 10-10 M to 10-5 M
Trial: NCT06285409
Drug: Carboprost
RxNorm normalized name: Carboprost
DrugBank: Carboprost (DB19356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing concentrations of carboprost from 10-10 M to 10-5 M
Trial: NCT04354649
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 5mg/kg PO daily
Trial: NCT04265105
Drug: fluticasone-vilanterol
RxNorm normalized name: fluticasone-vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid
Trial: NCT04969991
Drug: Varespladib
RxNorm normalized name: Varespladib
DrugBank: Varespladib (DB11909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg immediate-release oblong, white, film-coated tablet for oral administration
Trial: NCT05304533
Drug: MYK-224
RxNorm normalized name: MYK-461
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05304533
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05304533
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05720325
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupixent is an interleukin-4 receptor alpha antagonist
Trial: NCT04502680
Drug: Eribulin Mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
Trial: NCT06138041
Drug: intravenous lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
Trial: NCT06138041
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Same volume of normal saline in bolus and continuous infusion as lidocaine group.
Trial: NCT06385509
Drug: Jatenzo
RxNorm normalized name: Jatenzo
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 237 mg JATENZO twice daily
Trial: NCT05083117
Drug: XW001
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
Trial: NCT05966688
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of ethambutol.
Trial: NCT04794569
Drug: tinzaparin
RxNorm normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low molecular weight heparin
Trial: NCT04794569
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: direct oral anticoagulant
Trial: NCT05311813
Drug: Enoxaparin, Hydroxychloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
Trial: NCT05114460
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Naloxone
Trial: NCT05114460
Drug: Marijuana
RxNorm normalized name: Marijuana
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaped Marijuana